Update, November 2, 2026. HHS announced on October 28, and published on October 30, an interim policy on these six peptides. It says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding them when ten conditions are met, until a final rule decides each one. It covers 503A compounding only. KPV is covered only in topical and oral forms and Semax only as a nasal product. None of the six is FDA-approved or on the 503A bulks list, and no rule has been proposed. The HHS policy item has the conditions.
An FDA advisory committee voted on July 23 and 24, 2026 to recommend adding six peptides to the 503A bulks list, the list of substances state-licensed pharmacies may use to compound drugs for individual patients. The six were BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon. The committee voted against a seventh, emideltide.
What changed. FDA’s own reviewers had proposed against all seven in the agency’s briefing document. The committee disagreed by narrow margins; RAPS reported an 8 to 6 vote with one abstention for BPC-157 and KPV. FDA had not posted official vote minutes on its meeting page when this item was written.
What it means. The votes are advice. FDA’s briefing document says the agency does not intend to issue a final determination until it has considered the committee’s input and finished its reviews. Adding a substance to the bulks list takes a proposed rule, public comment and a final rule.
If you take this or are considering it. A committee vote and the HHS policy that followed are decisions about compounding and enforcement. Neither is evidence that a peptide works or is safe, and FDA’s own reviewers proposed against all seven. If you use one of these or a clinic has offered one, three questions show whether it even fits what HHS described: is there a prescription written for you, did a state-licensed pharmacy make it, and does the label name a single peptide? Blends fall outside the policy. As of November 2, 2026, written comments are open until November 13, and HHS says it may revisit the policy if a safety or quality problem appears.
What has not changed. None of these peptides is an FDA-approved drug, and none had been added to the 503A bulks list as of October 25, 2026. Products sold as “research use only” are still not legal to use on people. The BPC-157 guide and the FDA status tracker follow the next steps.